Mental health disorders like PTSD and depression might not be as much of a barrier to cardiac rehabilitation as was previously thought, according to a study of more than 85,000 U.S. veterans published in the Journal of the American Heart Association.

An expert consensus document endorsed by four major cardiology societies redefines cardiogenic shock based on patient descriptions, physical markers and a standardized set of vocabulary.

Low-dose daily aspirin may be effective as a preventive therapy for heart patients with symptomatic atherosclerotic disease, but in the general population the drug’s risk of intracranial bleeding outweighs any CV benefits it may have, according to a study published May 13 in JAMA Neurology.

CVD-related fatalities in individuals under 75 years old are on the rise in the U.K. for the first time in five decades, the Guardian reported May 12.

A machine learning algorithm can now predict death and MI more accurately than certified cardiologists, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT in Lisbon, Portugal, this May.

A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.

A study of more than 750 kids who were followed into their thirties has linked oral infections in childhood to CVD later in life—particularly subclinical carotid atherosclerosis.

After a successful safety and feasibility trial run, the FDA granted approval April 26 to the STEMI DTU (ST-Elevation Myocardial Infarction Door-to-Unloading) study, which will examine whether unloading the left ventricle prior to reperfusion can reduce myocardial damage and lead to fewer CV complications in STEMI patients.